The annual CPHI Worldwide was successfully held at the Messe Frankfurt in Germany on November 1-3, 2022. As the world-class international pharma industry event, CPHI Worldwide gathers the most significant pharmaceutical giants and leading companies around the world. Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) debuted at CPHI Worldwide as an exhibitor for the first time this year. Our representatives had in-depth exchanges with industry peers and customers and the event was considered as a complete success.

The exhibition area was about 160,000 sqm, with exhibits covering ingredients, machinery, equipment, technology, package and contract services. The exhibition covers each stage of the pharmaceutical supply chain, creating a one-stop global platform for every business demand.

Gan & Lee's booth design was based on brand and product characteristics. Many attendees were attracted to stop and talk. In addition, the products displayed include six insulin penfills, two pre-filled pens, insulin pens and needles approved in China. The products have received extensive attention from customers and industry insiders in the field of diabetes.

During the exhibition, Gan & Lee's business development team received nearly 500 customers from all over the world and held more than 70 meetings at the booth. They had in-depth exchanges with the BD teams of leading pharmaceutical companies in many countries on the future business cooperation model and feasibility. This exhibition is a great opportunity for the Gan & Lee brand to go to the international stage in the pharmaceutical industry, and we look forward to participating in CPHI Barcelona next year.

Reference:

1.CPHI https://www.CPHI.com/europe/en/about.html 

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.